GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » EBIT

CNTB (Connect Biopharma Holdings) EBIT : $-21.24 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings EBIT?

Connect Biopharma Holdings's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was $7.72 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was $-21.24 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Connect Biopharma Holdings's annualized ROC % for the quarter that ended in Jun. 2024 was 86.11%. Connect Biopharma Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 333.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Connect Biopharma Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 45.87%.

Connect Biopharma Holdings EBIT Historical Data

The historical data trend for Connect Biopharma Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings EBIT Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
-24.09 -119.26 -201.99 -117.77 -59.36

Connect Biopharma Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only -59.76 -58.01 -30.40 -28.96 7.72

Competitive Comparison of Connect Biopharma Holdings's EBIT

For the Biotechnology subindustry, Connect Biopharma Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's EV-to-EBIT falls into.


Connect Biopharma Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-21.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings  (NAS:CNTB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Connect Biopharma Holdings's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=10.176 * ( 1 - 0.78% )/( (18.526 + 4.924)/ 2 )
=10.0966272/11.725
=86.11 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=125.892 - 10.659 - ( 118.653 - max(0, 24.264 - 120.971+118.653))
=18.526

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=120.57 - 9.372 - ( 110.174 - max(0, 9.624 - 115.898+110.174))
=4.924

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Connect Biopharma Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=15.438/( ( (4.727 + max(-21.839, 0)) + (4.519 + max(-7.496, 0)) )/ 2 )
=15.438/( ( 4.727 + 4.519 )/ 2 )
=15.438/4.623
=333.94 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.14) - (10.659 + 13.32 + -3.5527136788005E-15)
=-21.839

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.876) - (9.372 + 0 + 0)
=-7.496

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Connect Biopharma Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-21.241/-46.307
=45.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Connect Biopharma Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » EBIT
Comparable Companies
RVPH VXRT PMVP THRX ANIX IFRX BDTX CDXC ABEO INO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130
Website
https://www.connectbiopharm.com
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.